<p>過去一週，幾隻生物科技股票的強勢減弱，在 Benzinga 的邊緣股票排名中，它們的動量評分出現了顯著下降。</p>
<h2>動量評分下降的四大生物科技股票</h2>
<p>在 Benzinga 的邊緣排名中，動量是基於股票的相對強度計算的，考慮了其價格波動和多個時間框架內的波動性，並與其他股票進行百分位排名。</p>
<p>在過去一週，以下生物科技股票的動量評分大幅下降，原因是什麼呢？</p>
<p><strong>另見：史蒂文·科恩的生物科技投資變得更加大膽——同時也更小</strong></p>
<h3>1. Capricor Therapeutics Inc.</h3>
<p><strong>Capricor Therapeutics Inc.</strong>（納斯達克股票代碼：CAPR）的股票在 FDA 發出拒絕其針對杜氏肌營養不良症的細胞療法 Deramiocel 申請的完整回應信後失去了動力。該機構指出了療效問題和公司生產流程的問題。</p>
<p>該股票年初至今下跌了 57.69%，過去一個月下跌了 17.58%，其動量評分在短短一週內從 77.57 降至 22.12。</p>
<p></p>
<p>根據 <strong>Benzinga 的邊緣股票排名</strong>，該股票在動量和價值方面得分較低，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票的更深入見解。</p>
<h3>2. Lava Therapeutics NV</h3>
<p>荷蘭生物科技公司 <strong>Lava Therapeutics NV</strong>（納斯達克股票代碼：LVTX）的動量評分下降了 46.74 點，從 82.03 降至 35.29。</p>
<p>該股票在公司發佈超出預期的第二季度淨虧損後失去了動量，緊接着 Jefferies 將其評級從 “買入” 下調至 “持有”。</p>
<p></p>
<p>在 <strong>Benzinga 的邊緣股票排名</strong> 中，該股票在動量和價值方面得分較低，但短期、中期和長期的價格趨勢較為有利。點擊 這裏 獲取該股票的更深入見解。</p>
<h3>3. Alaunos Therapeutics Inc.</h3>
<p>臨牀階段腫瘤學公司 <strong>Alaunos Therapeutics Inc.</strong>（納斯達克股票代碼：TCRT）的動量在一週內下降了 31.48 點，從 56.44 降至 24.96，主要是由於該股票自 7 月中旬以來的急劇下跌，且沒有主要催化劑或基本面新聞可歸咎於此。</p>
<p>該股票年初至今仍上漲 15.74%，在 7 月第二週從 52 周高點 6.20 美元下跌了 63%。</p>
<p></p>
<p>該股票的動量評分較低，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票、其同行和競爭對手的更深入見解。</p>
<h2>4. Champions Oncology Inc.</h2>
<p>總部位於新澤西的 <strong>Champions Oncology Inc.</strong>（納斯達克股票代碼：CSBR）在其令人失望的第二季度業績後承受壓力，報告了收入下降和虧損擴大。該股票年初至今下跌了 13.90%，從今年年初的 52 周高點下跌了 41.1%，導致其動量評分下降了 26.44 點，從 78.47 降至 52.03。</p>
<p></p>
<p>該股票在動量方面得分較高，但在價值和質量方面表現不佳，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票的更深入見解。</p>
<p><strong>閲讀更多：</strong></p>
<ul>
<li><strong>動量強勁的五大生物科技股票</strong></li>
</ul>
<p><em>圖片來源：Shutterstock</em></p>

TCRT

CSBR

<p>幾隻生物科技股票在過去一週的動量評分上出現了下降，顯示出實力減弱。值得注意的股票包括 Capricor Therapeutics，該公司在 FDA 拒絕其治療申請後大幅下跌，以及 Lava Therapeutics，該公司在遭遇超出預期的虧損後評級被下調。Alaunos Therapeutics 在沒有重大新聞的情況下也出現了下滑，而 Champions Oncology 則報告了令人失望的財報，導致其動量評分下降。總體來看，根據 Benzinga 的邊緣股票排名，這些股票在動量和價值方面顯示出不利趨勢</p>

<p>Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga’s Edge Stock Rankings witnessing a significant decline.</p>
<div class="lb-trans"><p>過去一週，幾隻生物科技股票的強勢減弱，在 Benzinga 的邊緣股票排名中，它們的動量評分出現了顯著下降。</p>
</div><h2>Top 4 Biotech Stocks With A Dip In Momentum Scores</h2>
<div class="lb-trans"><h2>動量評分下降的四大生物科技股票</h2>
</div><p>In Benzinga’s Edge Rankings, Momentum is calculated based on the relative strength of a stock, taking into consideration its price movements and volatility across multiple time frames, ranked as a percentile against other stocks.</p>
<div class="lb-trans"><p>在 Benzinga 的邊緣排名中，動量是基於股票的相對強度計算的，考慮了其價格波動和多個時間框架內的波動性，並與其他股票進行百分位排名。</p>
</div><p>Over the past week, the following biotech stocks have seen big declines in their respective momentum scores, and here’s why?</p>
<div class="lb-trans"><p>在過去一週，以下生物科技股票的動量評分大幅下降，原因是什麼呢？</p>
</div><p><strong>See Also: Steven Cohen’s Biotech Bets Are Getting Bolder — And Smaller</strong></p>
<div class="lb-trans"><p><strong>另見：史蒂文·科恩的生物科技投資變得更加大膽——同時也更小</strong></p>
</div><h3>1. Capricor Therapeutics Inc.</h3>
<div class="lb-trans"><h3>1. Capricor Therapeutics Inc.</h3>
</div><p>Shares of <strong>Capricor Therapeutics Inc.</strong>(NASDAQ: CAPR) have lost steam after the FDA issued a Complete Response Letter rejecting its application for Deramiocel, a cell therapy targeting Duchenne muscular dystrophy. The agency flagged both efficacy concerns and issues with the company's manufacturing processes.</p>
<div class="lb-trans"><p><strong>Capricor Therapeutics Inc.</strong>（納斯達克股票代碼：CAPR）的股票在 FDA 發出拒絕其針對杜氏肌營養不良症的細胞療法 Deramiocel 申請的完整回應信後失去了動力。該機構指出了療效問題和公司生產流程的問題。</p>
</div><p>The stock is down 57.69% year-to-date, and 17.58% over the past month, leading its Momentum scores to drop from 77.57 to 22.12 within just one week.</p>
<div class="lb-trans"><p>該股票年初至今下跌了 57.69%，過去一個月下跌了 17.58%，其動量評分在短短一週內從 77.57 降至 22.12。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>According to <strong>Benzinga’s Edge Stock Rankings</strong>, the stock scores poorly on Momentum and Value, with an unfavorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>根據 <strong>Benzinga 的邊緣股票排名</strong>，該股票在動量和價值方面得分較低，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票的更深入見解。</p>
</div><h3>2. Lava Therapeutics NV</h3>
<div class="lb-trans"><h3>2. Lava Therapeutics NV</h3>
</div><p>Dutch biotech company, <strong>Lava Therapeutics NV</strong> (NASDAQ: LVTX), is down 46.74 points in its Momentum score, dropping from 82.03 to 35.29.</p>
<div class="lb-trans"><p>荷蘭生物科技公司 <strong>Lava Therapeutics NV</strong>（納斯達克股票代碼：LVTX）的動量評分下降了 46.74 點，從 82.03 降至 35.29。</p>
</div><p>The stock lost its momentum after the company posted a wider-than-expected second-quarter net loss, which was quickly followed by a rating downgrade by Jefferies, from a “Buy” to a “Hold.”</p>
<div class="lb-trans"><p>該股票在公司發佈超出預期的第二季度淨虧損後失去了動量，緊接着 Jefferies 將其評級從 “買入” 下調至 “持有”。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock scores poorly on Momentum and Value in <strong>Benzinga’s Edge Stock Rankings</strong>, but has a favorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>在 <strong>Benzinga 的邊緣股票排名</strong> 中，該股票在動量和價值方面得分較低，但短期、中期和長期的價格趨勢較為有利。點擊 這裏 獲取該股票的更深入見解。</p>
</div><h3>3. Alaunos Therapeutics Inc.</h3>
<div class="lb-trans"><h3>3. Alaunos Therapeutics Inc.</h3>
</div><p>Clinical-stage oncology company, <strong>Alanunos Therapeutics Inc.</strong> (NASDAQ: TCRT), has seen its Momentum drop 31.48 points within a week, from 56.44 to 24.96, primarily driven by the steep decline in the stock starting mid-July, with no major catalyst or fundamental news to blame.</p>
<div class="lb-trans"><p>臨牀階段腫瘤學公司 <strong>Alaunos Therapeutics Inc.</strong>（納斯達克股票代碼：TCRT）的動量在一週內下降了 31.48 點，從 56.44 降至 24.96，主要是由於該股票自 7 月中旬以來的急劇下跌，且沒有主要催化劑或基本面新聞可歸咎於此。</p>
</div><p>The stock is still up 15.74% year-to-date, following a 63% decline from its 52-week high of $6.20 during the second week of July.</p>
<div class="lb-trans"><p>該股票年初至今仍上漲 15.74%，在 7 月第二週從 52 周高點 6.20 美元下跌了 63%。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock has a low momentum score, and has an unfavorable price trend in the short, medium and long-terms. Click here for deeper insights into the stock, its peers and competitors.</p>
<div class="lb-trans"><p>該股票的動量評分較低，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票、其同行和競爭對手的更深入見解。</p>
</div><h2>4. Champions Oncology Inc.</h2>
<div class="lb-trans"><h2>4. Champions Oncology Inc.</h2>
</div><p>New Jersey-based <strong>Champions Oncology Inc.</strong> (NASDAQ: CSBR) has been under pressure after its disappointing second quarter results, when it reported a drop in revenue, alongside widening losses. The stock is down 13.90 % year-to-date, and 41.1% from its 52-week high early this year, leading to a 26.44 point drop in its Momentum score, from 78.47 to 52.03.</p>
<div class="lb-trans"><p>總部位於新澤西的 <strong>Champions Oncology Inc.</strong>（納斯達克股票代碼：CSBR）在其令人失望的第二季度業績後承受壓力，報告了收入下降和虧損擴大。該股票年初至今下跌了 13.90%，從今年年初的 52 周高點下跌了 41.1%，導致其動量評分下降了 26.44 點，從 78.47 降至 52.03。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>The stock still scores high on Momentum, but does poorly on Value and Quality, with an unfavorable price trend in the short, medium and long terms. Click here for deeper insights into the stock.</p>
<div class="lb-trans"><p>該股票在動量方面得分較高，但在價值和質量方面表現不佳，短期、中期和長期的價格趨勢均不利。點擊 這裏 獲取該股票的更深入見解。</p>
</div><p><strong>Read More:</strong></p>
<div class="lb-trans"><p><strong>閲讀更多：</strong></p>
</div><ul>
<li><strong>Top 5 Biotech Stocks With Strong Momentum</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>動量強勁的五大生物科技股票</strong></li>
</ul>
</div><p><em>Photo courtesy: Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源：Shutterstock</em></p>
</div>

4 只生物科技股票表現出疲軟跡象：過去一週動量評分正在減弱